A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
A phase 1/2 trial of Bevacizumab, Fruquintinib and Docetaxel in advanced solid tumours, run by AskGene Pharma, Inc., now recruiting.
Overview
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT05867420 by AskGene Pharma, Inc., with 594 participants planned, started 2023-08-02 and due to reach its primary completion in 2026-12-31. Interventions recorded: ASKG915, Paclitaxel + Bevacizumab, Fruquintinib and Docetaxel.
Similar pages
not linked directly; found by shared links- TrialA Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Shares Docetaxel, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Shares Fruquintinib, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Shares Docetaxel, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Shares Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Shares Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.